This is a preview of subscription content, log in via an institution to check access.
Notes
2019 US dollars
HMG-CoA reductase inhibitors
Reference
Bagepally BS, et al. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. European Journal of Clinical Pharmacology : 27 Oct 2021. Available from: URL: http://doi.org/10.1007/s00228-021-03242-6
Rights and permissions
About this article
Cite this article
PCSK9 inhibitors not cost effective versus other antihyperlipidaemics. PharmacoEcon Outcomes News 891, 21 (2021). https://doi.org/10.1007/s40274-021-08179-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08179-8